GlaxoSmithKline News and Research

RSS

City of Hope exhibits current studies and data on cancer therapies at AACR

City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will showcase ongoing studies and data on chimeric antigen receptor T cell therapy, immunotherapy against solid tumors and more at the American Association for Cancer Research annual meeting from March 29 through April 3 in Atlanta.

22 Mar 2019

TGen and ABL sign agreement to distribute new TB test technology

n an important step toward eradicating tuberculosis, the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has signed a licensing agreement with an international biomedical firm, Advanced Biological Laboratories, to market and distribute TGen's patented Next Generation Sequencing-based TB test technology.

19 Mar 2019

Two-drug combinations containing calcium channel blocker significantly lowers BP

In the largest randomized controlled trial of treatment for high blood pressure ever conducted in sub-Saharan Africa, two frontline two-drug combinations that included the long-acting calcium channel blocker, amlodipine, were able to drive down blood pressure levels more than a third two-drug combination that did not include amlodipine, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

19 Mar 2019

Porvair Sciences to improve the diagnosis and treatment of ovarian cancer

Porvair Sciences reports on its involvement in a new £2.6 million project led by Swansea University (UK) that aims to dramatically improve the diagnosis and treatment of ovarian cancer.

From Chromatrap® - Porvair Sciences Ltd 27 Feb 2019

U.S.-based patient advocacy organizations received majority of pharma donations, finds study

A new study by Johns Hopkins Bloomberg School of Public Health researchers found that U.S.-based patient advocacy organizations received a disproportionate amount of contributions made by the world's 10 largest pharmaceutical companies in 2016.

23 Feb 2019

Drug combinations could become first-line treatment for metastatic kidney cancer

A combination of two drugs - one of them an immunotherapy agent - could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

18 Feb 2019

Cognetivity signs agreement to become ninth industry partner of Dementias Platform UK

Cognetivity Neurosciences Ltd. today announced that it has signed a commercial agreement with Dementias Platform UK to become its ninth industry partner.

25 Jan 2019

Unique data combination helps FinnGen researchers to fund links between genetic factors and health

The FinnGen study, launched in autumn 2017, is a broad academic-industrial collaboration between the Finnish biobanks and their respective Universities, University Hospitals, the Institute of Health and Welfare, the Finnish Red Cross Blood Service and now nine international pharmaceutical companies

23 Jan 2019

Researchers launch clinical trial to develop breath test for multiple cancers

Researchers have launched a clinical trial to develop a breath test, analyzing molecules that could indicate the presence of cancer at an early stage.

2 Jan 2019

IONTAS founder and pioneer in phage display technology attends Nobel Prize Award Ceremony

Dr. John McCafferty celebrates the success of phage display technology with Nobel Prize in Chemistry Laureates.

From FairJourney Biologics 12 Dec 2018

Ezogabine treatment reduces motor neuron excitability in ALS patients, study shows

Brian Wainger, MD, PhD, of the Healey Center for ALS at Massachusetts General Hospital presented initial, top-level results of a recently completed phase 2 clinical trial of ezogabine (also called retigabine) on December 9 at the Motor Neurone Disease Association annual meeting in Glasgow, Scotland.

11 Dec 2018

Study finds why people feel it easier to achieve small incremental goals

Thanks to a quirk in the way our brain evaluates goals, people feel it's easier to achieve a small incremental goal than to maintain the status quo, when both goals are assessed in isolation. This is especially true if the context is seen as unfavourable.

9 Nov 2018

WHO revise treatment guidelines of lymphatic filariasis due to CWRU-led study

Researchers from Case Western Reserve University School of Medicine have shown that a single "cocktail" of three pill-based anti-parasite medications is significantly more effective at killing microscopic larval worms in people diagnosed with lymphatic filariasis, commonly known as elephantiasis, than other standard two-drug combinations previously used in the global effort to eliminate this infectious disease.

9 Nov 2018

HIV-infected infants more likely to acquire congenital cytomegalovirus infection

Infants born to HIV-positive mothers had high rates of congenital cytomegalovirus, or CMV. Infants who also were infected before birth by the virus that causes AIDS were especially prone to CMV infection.

16 Oct 2018

Ritual for orthodox Jewish men may offer cardiovascular health benefits, study suggests

A pilot study led by researchers at the University of Cincinnati College of Medicine suggests Jewish men who practice wearing tefillin, which involves the tight wrapping of an arm with leather banding as part of daily prayer, may receive cardiovascular health benefits.

11 Oct 2018

Fina Biosolutions receives patent for expression and purification of the conjugate vaccine protein

Fina Biosolutions announces that the United States Patent and Trademark Office has issued a patent for expression and purification of the conjugate vaccine protein CRM197 in E. coli.

27 Sep 2018

New TB vaccine effective in half of the population in phase II trials

GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.

26 Sep 2018

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

GlaxoSmithKline plc and Innoviva, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion today supporting the use of Trelegy Ellipta in a broader group of patients with moderate to severe chronic obstructive pulmonary disease and that labeling, if approved, will be updated to further reflect its effect on exacerbations of COPD.

21 Sep 2018

Enrollment in opioid controlled substance agreement reduces primary care visits

The medical community has long known that patients on long-term opioid therapy often have significantly more health care visits.